Phase 3 Recruiting Network
This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care …
Sponsor: Children's Oncology Group
NCT ID: NCT05602194
Sites in Virginia: - University of Virginia Cancer Center — Charlottesville, Virginia
- Inova Fairfax Hospital — Falls Church, Virginia
- Children's Hospital of The King's Daughters — Norfolk, Virginia
- VCU Massey Comprehensive Cancer Center — Richmond, Virginia
- Carilion Children's — Roanoke, Virginia
Phase 3 Recruiting Industry
This study will compare the effects of Quizartinib versus placebo in combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) negative acute myeloid leukemia (AM…
Sponsor: Daiichi Sankyo
NCT ID: NCT06578247
Sites in Virginia: - Uva Health System — Charlottesville, Virginia
- Virginia Commonwealth University (Vcu) Massey Cancer Center — Richmond, Virginia
Phase 3 Recruiting Academic/Other
A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin \[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st r…
Sponsor: PedAL BCU, LLC
NCT ID: NCT05183035
Sites in Virginia: - Children's Hospital of Richmond at Virginia Commonwealth University — Richmond, Virginia
Phase 3 Recruiting Industry
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136559
Sites in Virginia: - University of Virginia Cancer Center ( Site 0040) — Charlottesville, Virginia
- Inova Schar Cancer Institute ( Site 0015) — Fairfax, Virginia
- Virginia Commonwealth University (VCU) Medical Center ( Site 0030) — Richmond, Virginia
Phase 3 Recruiting Industry
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with eligible genetic alterations. Ziftomenib is a type of therapy known to target the menin pathway in cancer cells. This…
Sponsor: Kura Oncology, Inc.
NCT ID: NCT07007312
Sites in Virginia: - University of Virginia School of Medicine — Charlottesville, Virginia
- Virginia Cancer Specialists — Manassas, Virginia
Phase 3 Recruiting Industry
The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been c…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT01804686
Sites in Virginia: - University of Virginia — Charlottesville, Virginia
Phase 3 Recruiting Industry
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety of venetoclax in combination with obinutuzumab or acalabrutinib in the treatment of CLL. Adverse even…
Sponsor: AbbVie
NCT ID: NCT06428019
Sites in Virginia: - Virginia Cancer Specialists - Fairfax /ID# 268155 — Fairfax, Virginia
Phase 3 Recruiting Industry
The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part …
Sponsor: Loxo Oncology, Inc.
NCT ID: NCT05254743
Sites in Virginia: - Virginia Cancer Institute — Richmond, Virginia
Phase 3 Recruiting Industry
This Phase 3 study in adult participants with newly diagnosed low-risk APL will evaluate the efficacy, safety, and PK of an oral capsule formulation of ATO, in combination with ATRA.
Sponsor: Quetzal Therapeutics
NCT ID: NCT07504458
Sites in Virginia: - Quetzal Site 3 — Charlottesville, Virginia
Phase 2 Recruiting NIH
This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myelo…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564390
Sites in Virginia: - University of Virginia Cancer Center — Charlottesville, Virginia
- Inova Schar Cancer Institute — Fairfax, Virginia
- Inova Fairfax Hospital — Falls Church, Virginia
- VCU Massey Comprehensive Cancer Center — Richmond, Virginia
Phase 2 Recruiting NIH
This phase II trial studies how well inotuzumab ozogamicin and blinatumomab with or without ponatinib work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back after a period…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03739814
Sites in Virginia: - VCU Massey Comprehensive Cancer Center — Richmond, Virginia
Phase 2 Recruiting NIH
This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML)…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554406
Sites in Virginia: - University of Virginia Cancer Center — Charlottesville, Virginia
- Inova Schar Cancer Institute — Fairfax, Virginia
- Inova Fairfax Hospital — Falls Church, Virginia
Phase 2 Recruiting NIH
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in Virginia: - Inova Fairfax Hospital — Falls Church, Virginia
- Children's Hospital of The King's Daughters — Norfolk, Virginia
Phase 2 Recruiting NIH
This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554393
Sites in Virginia: - University of Virginia Cancer Center — Charlottesville, Virginia
- Inova Schar Cancer Institute — Fairfax, Virginia
- Inova Fairfax Hospital — Falls Church, Virginia
Phase 1, Phase 2 Recruiting Academic/Other
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back a…
Sponsor: PedAL BCU, LLC
NCT ID: NCT04726241
Sites in Virginia: - University of Virginia Cancer Center — Charlottesville, Virginia
- Inova Fairfax Hospital — Falls Church, Virginia
- Children's Hospital of The King's Daughters — Norfolk, Virginia
- VCU Massey Comprehensive Cancer Center — Richmond, Virginia
- Carilion Children's — Roanoke, Virginia
Phase 2 Recruiting NIH
This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in Virginia: - University of Virginia Cancer Center — Charlottesville, Virginia
- Children's Hospital of The King's Daughters — Norfolk, Virginia
- VCU Massey Comprehensive Cancer Center — Richmond, Virginia
- Carilion Children's — Roanoke, Virginia
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to determine the recommended dose of JCAR017…
Sponsor: Juno Therapeutics, a Subsidiary of Celgene
NCT ID: NCT03331198
Sites in Virginia: - Local Institution - 0113 — Charlottesville, Virginia
- Local Institution - 0087 — Richmond, Virginia
- Virginia Commonwealth University — Richmond, Virginia
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing of ibrutinib is either proactively reduced or reactively modified in response to adverse ev…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT05963074
Sites in Virginia: - Virginia Cancer Specialists — Manassas, Virginia
- Virginia Oncology Associates — Virginia Beach, Virginia
Phase 2 Recruiting Industry
The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of tre…
Sponsor: Loxo Oncology, Inc.
NCT ID: NCT06588478
Sites in Virginia: - USO-Virginia Oncology Associates — Hampton, Virginia
Phase 1, Phase 2 Recruiting Industry
This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or cytotoxic lymph…
Sponsor: Dren Bio
NCT ID: NCT05475925
Sites in Virginia: - Dren Investigational Site — Charlottesville, Virginia
- Dren Investigational Site — Fairfax, Virginia
Phase 2 Recruiting Network
The purpose of this clinical trial is to compare drug combinations to learn which drugs work best to prevent graft-versus-host-disease (GVHD) in people who have received a stem cell transplant. The source of stem cells is from someone who …
Sponsor: Center for International Blood and Marrow Transplant Research
NCT ID: NCT06859424
Sites in Virginia: - University of Virginia — Charlottesville, Virginia
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, global multicentre, open-label, single-arm, dose escalation and dose optimisation study of AZD0486 to evaluate the safety, tolerability, and efficacy of AZD0486 monotherapy in participants with R/R B ALL who have recei…
Sponsor: AstraZeneca
NCT ID: NCT06137118
Sites in Virginia: - Research Site — Richmond, Virginia
Phase 1, Phase 2 Recruiting Industry
This Phase I/II trial evaluates the safety and preliminary efficacy of DFP-10917 combined with venetoclax in relapsed or refractory acute myeloid leukemia. DFP-10917 is given as a 14-day continuous IV infusion every 28 days, alongside a 14…
Sponsor: Delta-Fly Pharma, Inc.
NCT ID: NCT06382168
Sites in Virginia: - University of Virginia Cancer Center — Charlottesville, Virginia
Phase 1 Recruiting NIH
This phase Ib trial tests the safety, side effects, and best dose of SNDX-5613 when given in combination with the standard chemotherapy treatment (daunorubicin and cytarabine) in treating patients with newly diagnosed acute myeloid leukemi…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05886049
Sites in Virginia: - University of Virginia Cancer Center — Charlottesville, Virginia
Phase 1 Recruiting Industry
The objective of this study to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of BL-M11D1 in patients with relapsed/refractory acute myeloid leukemia.
Sponsor: SystImmune Inc.
NCT ID: NCT06714591
Sites in Virginia: - Virginia Cancer Specialists — Fairfax, Virginia
- Oncology & Hematology Associates of Southwest Virginia, Inc. — Roanoke, Virginia